GlaxoSmithKline (GSK) wants everyone, including the FDA, to know that its diabetes drug Avadia is "safe and effective when used appropriately."
Almost everyone else thinks that the drug increases risk of heart problems.
A Food and Drug Administration safety scientist today said that "GlaxoSmithKline Plc’s diabetes pill Avandia should be removed from the market because of heart risks," according to Bloomberg.
On May 27, a prominent researcher wrote in The New England Journal of Medicine that the drug increased the risk of heart attack.
GSK wants to believe that the drug is OK, because if it is pulled from the US market its shareholders get hammered. Its stock is near 52-week lows, and it appears that it is going to get worse.
Douglas A. McIntyre
Sponsored: Find a Qualified Financial Advisor
Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
